ANTONIO JOSÉ
CARUZ ARCOS
CATEDRATICO DE UNIVERSIDAD
Antonio
Rivero Román
Publicacions en què col·labora amb Antonio Rivero Román (29)
2024
-
Impact of Human Leukocyte Antigen Allele-Killer Cell Immunoglobulin-like Receptor Partners on Sexually Transmitted Human Immunodeficiency Virus Type 1 Infection
Journal of Infectious Diseases, Vol. 230, Núm. 5, pp. e1077-e1081
2021
-
Cd46 genetic variability and hiv-1 infection susceptibility
Cells, Vol. 10, Núm. 11
2016
-
Common haplotypes in CD209 promoter and susceptibility to HIV-1 infection in intravenous drug users
Infection, Genetics and Evolution, Vol. 45, pp. 20-25
2015
-
Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection
Genes and Immunity, Vol. 16, Núm. 2, pp. 134-141
-
IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection
AIDS
-
Longitudinal evaluation of hepatitis C viral persistence in HIV-infected patients with spontaneous hepatitis C clearance
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 11, pp. 2171-2175
2014
-
A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers
Liver International, Vol. 34, Núm. 4, pp. 558-566
-
Association of low-density lipoprotein receptor genotypes with hepatitis C viral load
Genes and Immunity, Vol. 15, Núm. 1, pp. 16-24
-
IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians
PLoS ONE, Vol. 9, Núm. 4
2013
-
A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients
Journal of Antimicrobial Chemotherapy, Vol. 68, Núm. 4, pp. 915-921
-
Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV
Infection, Vol. 41, Núm. 1, pp. 21-26
-
Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 32, Núm. 11, pp. 1427-1435
-
Natural Killer KIR3DS1 Is Closely Associated with HCV Viral Clearance and Sustained Virological Response in HIV/HCV Patients
PLoS ONE, Vol. 8, Núm. 4
-
Pegylated interferon plus ribavirin is suboptimal inIL28B CC carriers without rapid response
Journal of Infection, Vol. 67, Núm. 1, pp. 59-64
-
Short communication: Atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C
AIDS Research and Human Retroviruses, Vol. 29, Núm. 2, pp. 223-225
-
The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylatedinterferon/ ribavirin treatment varies according to hepatitis C virus-1 subtype
AIDS, Vol. 27, Núm. 12, pp. 1941-1947
-
Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection
AIDS, Vol. 27, Núm. 17, pp. 2715-2724
2012
-
Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4
Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 1, pp. 202-205
-
Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients
PLoS ONE, Vol. 7, Núm. 11
-
Differences in virological response to peginterferon-a plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b
Journal of Acquired Immune Deficiency Syndromes, Vol. 60, Núm. 2, pp. 117-123